Skip to main content
TipRanks
Go Ultimate75% OFF

Quantum Computing Earnings Call Highlights Growth and Execution Challenges

Quantum Computing Earnings Call Highlights Growth and Execution Challenges
Image source: Shutterstock

Quantum Computing ((QUBT)) has held its Q3 earnings call. Read on for the main highlights of the call.

Quantum Computing’s call was broadly optimistic, led by record revenue, strong liquidity, acquisitions and progress toward scalable quantum manufacturing. Still, the company remains early in commercialization, with a 4.5% gross margin, a larger operating-cost base, a sizable net loss and uneven order timing tempering the positive operational picture.

Record Third-Quarter Revenue

QCI reported record third-quarter revenue of $9.5 million, up from $384 thousand a year earlier. The quarter also surpassed the $9.2 million generated during the entire first half of 2026, with photonic products for aerospace, government and industrial customers driving sales.

Acquisitions Build a Broader Foundation

Acquisitions completed earlier this year added established products, customer relationships, manufacturing capabilities and commercial operations. Management said the purchases also support QCI’s longer-term quantum technology roadmap and provide a stronger base for growth.

Customer and Partner Momentum

QCI provided cloud access to its Dirac system for Hamad Khalifa University in Qatar and installed a Dirac optimization system at a leading global consulting firm. It also agreed to work with Planck Dynamics on a neural wave reservoir computer for defense applications.

Dirac-3 Launch Advances

QCI announced Dirac-3, its next-generation quantum optimization machine, which is designed to handle problems involving up to 9.98 thousand variables. The company expects the first customer shipment in the fourth quarter, with both cloud access and on-premise options available.

Benchmark Results Show Promise

Management said published tests showed Dirac-3 outperforming Hexaly and other leading classical optimization algorithms on most tested problems. The company also acknowledged that performance was comparable to, or less optimal than, classical alternatives on some problems.

Dirac-3 Could Expand the Pipeline

Management reported strong customer reactions to Dirac-3’s larger variable capacity and solution quality, including surprise from some online users. Existing Dirac-2 customers may upgrade, while the system’s higher capacity could open additional application areas.

Biotech and Clinical Research Opportunity

QCI is working with ImmuBio to explore direct optimization AI and conventional analytics for clinical research data. Potential uses include drug discovery, patient scheduling and clinical-trial studies involving biomarkers and Phase 1, Phase 2 and Phase 3 research.

Photonics Platform Supports Multiple Markets

QCI’s platform extends beyond computing into sensing and communications. The company is combining photonic design, chip manufacturing and advanced packaging at facilities in North Carolina and Arizona to support proprietary quantum systems and established photonics markets.

Portfolio Roadmap Reaches Key Milestone

Management said QCI achieved all objectives in its 2024-2026 portfolio roadmap. The company is now shifting its focus toward scaling manufacturing and product lines, with the goal of making quantum systems smaller, more capable and easier to deploy.

Integration and Manufacturing Are Priorities

Over the next 12 to 24 months, QCI plans to expand its commercial business, scale manufacturing and advance its quantum portfolio. The company is coordinating operations across eight states and 11 facilities, emphasizing better integration rather than facility consolidation.

Enhanced Acquisition Accelerates Fab 2

QCI’s original greenfield plan called for Fab 2 to be completed around the end of 2028. Management said the Enhanced acquisition has accelerated that roadmap by adding advanced-packaging capabilities that can expand manufacturing capacity and support quantum products.

Heterogeneous Circuits Move Closer

QCI’s internal photonic integrated-circuit team is working with the Enhanced manufacturing group. Management expects to demonstrate heterogeneous integrated circuits within 12 to 18 months, while noting that the milestone could arrive sooner.

Liquidity Remains a Major Strength

QCI ended the quarter with approximately $1.3 billion in cash, cash equivalents and investments, $1.6 billion in total assets and $47.7 million in liabilities. Working capital was about $916.9 million, and management said liquidity should fund operations for at least the next 12 months.

Backlog Provides a Revenue Base

Contract backlog stood at approximately $39.1 million at quarter end. Management said backlog generally converts to revenue over 12 to 18 months, with most expected to be recognized within the next year, although complex products may require longer delivery periods.

Interest Income Jumps

Interest and other income rose to $13 million in the third quarter from $3.5 million a year earlier. The increase mainly reflected interest earned on QCI’s larger cash and investment balances, providing an important offset to operating costs.

Large Fab 2 Investment Planned

QCI has earmarked several hundred million dollars for capital expenditures and investments, including approximately $70 million to $80 million for Enhanced Fab 2. Equipment orders have begun, with a significant portion of the spending expected before March 31 of next year.

Room-Temperature Design Offers Advantages

Management highlighted that Dirac systems operate at room temperature and use relatively little power. Unlike many competing approaches, they do not require specialized cryogenic infrastructure, which could reduce deployment costs and technical complexity.

Data-Center Optimization Could Add Demand

QCI’s internal research is examining whether Dirac optimization can improve the use of computing resources in data centers. Management described the early findings as encouraging, while stressing that the opportunity still requires further evaluation before it can become a commercial offering.

Gross Margin Remains Low

QCI generated $428 thousand in gross profit on $9.5 million of revenue, producing a 4.5% gross margin. Management acknowledged that margins remain modest, highlighting the gap between current sales growth and broader operating profitability.

Net Loss Widens

The company reported a third-quarter net loss of $15.1 million, or $0.07 per basic share, compared with net income of $2.4 million, or $0.01 per share, a year earlier. Higher operating expenses and smaller mark-to-market gains on a warrant derivative were major factors.

Operating Expenses Rise Sharply

Operating expenses increased to $29 million from $10.5 million in the prior-year quarter. The rise reflected higher personnel costs tied to expanded research, development, sales and marketing activity, along with approximately $1 million in acquisition-related expenses.

Backlog Falls Sequentially

Backlog declined by approximately $2 million to $3 million from the previous quarter. Management described revenue and contract awards as lumpy, explaining that backlog can fluctuate as contracted orders are converted into reported revenue.

Government and Aerospace Dominate

Approximately 70% of current revenue and backlog is tied to aerospace and government work, much of it through subcontracts. Management expects the mix to move closer to 50% over time as commercial products mature and private-sector sales expand.

International Expansion Faces Barriers

Most current sales and backlog are domestic, with only a few small overseas sales. Management said geopolitical conditions, export controls and ITAR requirements make international growth more difficult, describing a 50% international mix as aggressive in the near term.

Order Timing Remains Difficult to Predict

QCI is not providing formal revenue guidance because the timing of orders and deliveries remains difficult to forecast. Management expects quarter-to-quarter lumpiness as the company moves from technology development toward broader commercialization.

Commercialization Is Still Early

Some QCI applications are commercially available, but others require additional development and validation. Management characterized the ImmuBio work as early and said adoption is likely to progress at different speeds across markets and use cases.

Dirac-3 Is Not Superior on Every Problem

Although Dirac-3 performed better on most benchmark problems, management said some results were comparable to or less optimal than classical solutions. The company also declined to claim that it has achieved quantum supremacy, maintaining a cautious view of the technology’s current position.

Hiring Adds to the Cost Base

QCI had more than 330 employees at quarter end, up from approximately 310 to 320 at the end of the second quarter, and continues to hire. Management said the current expense level is a reasonable run-rate estimate, excluding trailing merger costs, but expenses should rise as headcount grows.

Complex Integration Work Continues

QCI is still integrating accounting, manufacturing systems, teams and workflows across eight states and 11 facilities. Management said coordinating these activities remains a significant challenge as the company works toward scalable quantum manufacturing.

Forward-Looking Guidance

QCI expects to ship the first Dirac-3 system in the fourth quarter and focus over the next 12 to 24 months on commercial growth, manufacturing scale and portfolio development. The company is not issuing formal guidance, but expects most of its $39.1 million backlog to convert to revenue within 12 months, while targeting heterogeneous circuit demonstrations within 12 to 18 months.

QCI’s earnings call presented a company with strong liquidity, expanding capabilities and visible product momentum, particularly around Dirac-3 and manufacturing. However, low margins, rising costs, a wider loss, concentrated customers and uneven orders show that the investment case still depends on converting technical progress into repeatable commercial revenue.

Disclaimer & DisclosureReport an Issue

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!